How would you treat newly diagnosed metastatic HER2 positive breast cancer with liquid NGS revealed ERBB2 L755S mutation (a marker for resistance against trastuzumab)?
1 Answer
Mednet Member
Medical Oncology · Heywood Hospital
Answered on
Neratinib
Join for free or sign in to see the full answer